AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 131 min read$PTCT

Boulding Mark Elliott sold $12K of PTCT

Boulding Mark Elliott (EXEC. VP AND CLO) sold 192 shares of PTC THERAPEUTICS, INC. (PTCT) at $64.26 on 2026-10-09 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Boulding Mark Elliott
Published Oct 13, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 9:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PTCT
Neutral
high confidence
Mentioned
$PTCT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTCTNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock materially.

02

Market read

Minor insider sell with limited trading relevance.

03

What to watch

Potential tax planning or portfolio rebalancing unrelated to company fundamentals.

Relevance 2/10Novelty 2/10Timing: after-hours filing on 2026-10-13

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$PTCTNeutralHigh confidence
Context

Executive VP and CLO Mark Elliott sold 192 shares for $12,337.92 via a 10b5-1 plan, reducing his stake to 105,272 shares.

Expected impact

likely slight pressure as the market prices in the insider sale

Evidence & confidence

The sale amount is small relative to total holdings and typical trading volume, so impact is limited.

Market effects

Sector

None significant for the biotech sector.

Regional

No broader regional effect.

Global

Limited to PTCT investors.

Counterpoint

What could challenge this read

The sale could be routine and not indicative of negative sentiment.

Key entities

  • person
    Mark Elliott

    Executive Vice President and Chief Legal Officer of PTC Therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTCT insider trading history →

Related articles

OCT 30
$PTCTMed

PTC Therapeutics Inc (PTCT) Q3 2026 Earnings Call Highlights: Record Revenue, Raised

PTC Therapeutics (PTCT) reported Q3 2026 earnings, raising guidance driven by Sephience growth. CEO Matthew Klein highlighted steady U.S. growth and ex-U.S. acceleration in 2027, with a $2B+ peak sales opportunity. The company expects ST920 Fabry gene therapy launch in 2027, with potential approval and incremental launch costs. Voraplan-Huntington's Type C meeting delayed to Q1 2027 due to FDA scheduling. PTC has $2.13B cash for potential business development.

finance.yahoo.com2 min
OCT 30
$PTCTMed

PTC Therapeutics Q3 Earnings Call Highlights

PTC Therapeutics reported Q3 earnings, highlighting growth in Sephience patients, including therapy-naive adults and those switching from Kuvan. The company expects peak sales of over $2B for Sephience, with the U.S. driving the majority. International growth was noted in Japan and other regions, with reimbursement negotiations ongoing in Europe. PTC acquired ST-920, a gene therapy for Fabry disease, for $111M upfront.

finance.yahoo.com2 min